Palisade Bio (PALI) EPS (Weighted Average and Diluted) (2016 - 2026)
Palisade Bio (PALI) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 89.36% year-over-year from -$0.03 in Q1 2025, and down 104.63% on a QoQ basis from $1.08 in Q4 2025.
Palisade Bio (PALI) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 89.36% year-over-year to -$0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.07 (up 101.03% YoY) and the FY2025 annual result came in at -$0.3, up 97.06% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$0.05 in Q1 2026 per PALI's latest filing, from $1.08 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.87 in Q4 2022 and bottomed at -$12.96 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$3.32 (2024), against an average of -$3.5.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) tumbled 1076.19%; it then surged 256.52% in 2025.
- Tracing PALI's EPS (Weighted Average and Diluted) over 5 years: stood at $1.87 in 2022, then sank by 301.6% to -$3.77 in 2023, then soared by 81.7% to -$0.69 in 2024, then soared by 256.52% to $1.08 in 2025, then plunged by 104.63% to -$0.05 in 2026.
- Per Business Quant, the three latest PALI EPS (Weighted Average and Diluted) figures stand at -$0.05 (Q1 2026), $1.08 (Q4 2025), and -$0.38 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | 1.08 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -0.47 |
| Dec 31, 2024 | -0.69 |
| Sep 30, 2024 | -2.32 |
| Jun 30, 2024 | -3.32 |
| Mar 31, 2024 | -4.59 |
| Dec 31, 2023 | -3.77 |
| Sep 30, 2023 | -7.38 |
| Jun 30, 2023 | -7.93 |
| Mar 31, 2023 | -8.13 |
| Dec 31, 2022 | 1.87 |
| Sep 30, 2022 | -4.10 |
| Jun 30, 2022 | -5.77 |
| Mar 31, 2022 | -12.96 |
| Dec 31, 2021 | -165.61 |
| Sep 30, 2021 | 0.42 |
| Jun 30, 2021 | -4.10 |
| Dec 31, 2020 | -1.53 |
| Sep 30, 2020 | -0.66 |
| Jun 30, 2020 | -0.67 |
| Sep 30, 2018 | -0.12 |
| Sep 30, 2017 | -0.18 |
| Sep 30, 2016 | -0.59 |